Not recruiting
Ovarian low malignant potential tumour
Not recruitingInvestigationalNo placebo
Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer
InvestigationalNo placebo
- Disease:Ovarian low malignant potential tumour
- Substances:Catequentinib Dihydrochloride
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Catequentinib Dihydrochloride
- Sponsor:Advenchen Laboratories LLC

